


Prevalence Of Chronic Diseases Due To Unhealthy Habits Drives The Metabolic Disorders Drugs Market

The Business Research Company's Metabolic Disorders Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, January 28, 2022 /EINPresswire.com/ --

The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. According to TBRC's [metabolic disorders drugs market research](#), these factors are expected to increase the patient pool globally, thereby driving the market during the forecast period.



Read More On The Global Metabolic Disorders Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/metabolic-disorder-drugs-global-market-report>

Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases.

The global [metabolic disorders drugs market size](#) is expected to grow from \$82.05 billion in 2021 to \$90.83 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The metabolic disorders drugs market share is expected to reach \$205.11 billion in 2026 at a CAGR of 22.6%.

Major players covered in the global metabolic disorders drugs industry are Novo Nordisk, Eli Lilly And Company, Novartis AG, Sanofi S.A, Merck & Co, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH and Dainippon Sumitomo Pharma.

TBRC's global metabolic disorders drugs market analysis report is segmented by type into anti diabetics drugs, anti-thyroid drugs, others (hyperparathyroidism, hypopituitarism, hypoadrenalism), by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a metabolic disorders drugs market overview, metabolic disorders drugs market forecast, metabolic disorders drugs market size and metabolic disorders drugs market growth for the whole market, metabolic disorders drugs market segments, geographies, metabolic disorders drugs market trends, metabolic disorders drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Metabolic Disorders Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2139&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Anti-Thyroid Drugs Global Market Report 2021 - By Drug Type (Thionamides (Inhibition Of Hormone Synthesis), Iodides (Inhibition Of Hormone Release)), By Route of Administration (Oral, Intravenous), By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report>

Drugs For Hormonal Replacement Therapy Global Market Report 2021 - By Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause), By Route of Administration (Oral, Parental), COVID-19 Impact and Recovery

<https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report>

Parathyroid Hormone Global Market Report 2021 - By Disease Type (Hypocalcemia, Hypoparathyroidism), By End-User (Hospitals, Clinics), By Product Type (Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/parathyroid-hormone-global-market-report-2020-30-covid-19-growth-and-change>

Know More About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561749812>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.